-
SUPERNUS PHARMACEUTICALS, INC. v. PAR PHARMACEUTICAL COMPANIES, INC. et al DC
- 2:15-cv-00326
- D.N.J.
- Judge: Susan D. Wigenton
+1
- Filed: 01/16/2015
- Closed: 10/16/2015
- Latest Docket Entry: 10/16/2015
- PACER
- Docket updated daily
1
Plaintiff
2
Defendants
1
Accused
Product
4
Patents-in-Suit
274
Days in
Litigation
-
SUPERNUS PHARMACEUTICALS, INC. v. PAR PHARMACEUTICAL COMPANIES, INC. et al DC
- 2:15-cv-00326
- D.N.J.
- Judge: Susan D. Wigenton
+1
- Filed: 01/16/2015
- Closed: 10/16/2015
- Latest Docket Entry: 10/16/2015
- PACER
- Docket updated daily
Causes of Action
Infringement
Willful Patent Infringement
Assigned Judge
Outcome Summary
- Patent Information
-
Infringement
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| topiramate oral capsule product under Abbreviated New Drug Application No. 205976 Supernus’ Trokendi XR® product | US 8,298,576 B2 | All Asserted Claims |
Infringement
Entry 67
|
| topiramate oral capsule product under Abbreviated New Drug Application No. 205976 Supernus’ Trokendi XR® product | US 8,298,580 B2 | All Asserted Claims |
Infringement
Entry 67
|
| topiramate oral capsule product under Abbreviated New Drug Application No. 205976 Supernus’ Trokendi XR® product | US 8,663,683 B2 | All Asserted Claims |
Infringement
Entry 67
|
| topiramate oral capsule product under Abbreviated New Drug Application No. 205976 Supernus’ Trokendi XR® product | US 8,877,248 B1 | All Asserted Claims |
Infringement
Entry 67
|
Par Pharmaceutical, Inc.
- 4 Details
| Accused Product | Patent # | Claim # | Outcome |
|---|---|---|---|
| topiramate oral capsule product under Abbreviated New Drug Application No. 205976 Supernus’ Trokendi XR® product | US 8,298,576 B2 | All Asserted Claims |
Infringement
Entry 67
|
| topiramate oral capsule product under Abbreviated New Drug Application No. 205976 Supernus’ Trokendi XR® product | US 8,298,580 B2 | All Asserted Claims |
Infringement
Entry 67
|
| topiramate oral capsule product under Abbreviated New Drug Application No. 205976 Supernus’ Trokendi XR® product | US 8,663,683 B2 | All Asserted Claims |
Infringement
Entry 67
|
| topiramate oral capsule product under Abbreviated New Drug Application No. 205976 Supernus’ Trokendi XR® product | US 8,877,248 B1 | All Asserted Claims |
Infringement
Entry 67
|
